The process of cell cycle involves 4 stages: G1, S, G2 and M phases. The cell cycle inhibitors make the process slower or they completely stop the cell division. This is an important attribute of Cell Cycle Inhibitors Therapeutics for the cancer therapy as the cancer cells divide and grow continuously.
Cell cycle regulation involves processes like activation or inactivation of several regulatory factors under the observation of checkpoints. Cell cycle regulation acts like a network and regulates the cell cycle by targeting various pathways that guide cell division. Cyclin-dependent kinases (Cdks) and other checkpoints which play a pivotal role in driving the cell engine during all phases of cell cycle, are the supreme targets for anticancer treatment. In recent past, cell cycle inhibitors therapeutics have become a major highlight of tumor treatment.
Cancer Researchers are focused on finding Cell Cycle Inhibitors Therapeutics as a cutting edge oncology treatment module. Some of the key factors that are driving the growth of the Cell Cycle Inhibitors Therapeutics Market include, rise in R&D spending and extensive oncology research worldwide. A series of clinical studies on cell cycle inhibitors have shown that a single mechanism of action can have judicious effects on cancer cells. The Cell Cycle Inhibitors therapeutics are studied rigorously in numerous clinical trials making Cell Cycle Inhibitors Therapeutics market a very promising field for anticancer treatment. Increasing cancer prevalence globally, increasing incidences of cancer and changing lifestyle tend to drive the growth of Cell Cycle Inhibitors Therapeutics market. As reported more than 1.7 million new cases of cancer were seen in 2018 in the US. And the rate of cancer mortality is 163 per 100000 people. All these factors contribute towards driving the Cell Cycle Inhibitors Therapeutics market. Despite of intensive research done on Cell Cycle Inhibitors Therapeutics, many have failed in the clinical trials. This is a major setback for the Cell Cycle Inhibitors Therapeutics market. Many of the future proposed drugs have failed to selectively destroy cancer cells. These drugs are also having severe cytotoxic effects on remaining normal cells. These factors can be major restraints to the Cell Cycle Inhibitors Therapeutics market. Also cost of these inhibitors is higher and cannot be affordable by people in lower and middle economic regions.
Based on the type of phase of the cell cycle, the global Cell Cycle Inhibitors Therapeutics Market is segmented into:
Based on route of administration, the global Cell Cycle Inhibitors Therapeutics Market is segmented into:
Based on target pathway, the global Cell Cycle Inhibitors Therapeutics Market is segmented into:
Based on distribution channels, the global Cell Cycle Inhibitors Therapeutics Market is segmented into:
The combination of traditional cytotoxic chemotherapeutic drugs and Cell Cycle Inhibitors Therapeutics together accelerates the anti-cancer effect making it a hot spot in the current oncology treatment scenario. As per Preclinical and clinical data, Cell Cycle Inhibitors Therapeutics could have efficacy in many types of cancer making it the most attractive anticancer therapy and a lucrative opportunity for Cell Cycle Inhibitors Therapeutics market players. Based on type of phases, the S-phase Cell Cycle Inhibitors are more studied and many drugs are available targeting the S phase of cell cycle. Based on target pathways, most of the Cell Cycle Inhibitors Therapeutics involve targeting CD Kinase and hence CDK kinase inhibitors are the prime targets among all Cell Cycle Inhibitors. The market is segmented based on type of inhibitor, target disease and route of administration. Specific Cell Cycle Inhibitors Therapeutics are preferred targets for specific types of cancer like breast, lung and ovaries etc.
With increasing extensive research and development activities in North America, the market for Cell Cycle Inhibitors Therapeutics is expected to hold a significant share of the market. Majority of the research and development activities are carried out by key players based out of the US and UK. Asia Pacific countries like Japan, China, India and Australia have shown growth in number of research and developments projects carried out in the recent years. Europe is expected to be the next most lucrative region followed by Asia Pacific for investments in Cell Cycle Inhibitors Therapeutics research.
Some of the key players in the market include, Pfizer Inc., Sanofi, Eli Lilly and Company, Novartis, Bristol-Myers Squibb Company, Merck KGaA, GlaxoSmithKline plc, Cipla Inc, Novartis AG, Dr. Reddy’s Laboratories Ltd and AstraZeneca and others.
The report covers exhaustive analysis on:
Regional analysis includes